Kongens Lyngby, Denmark, November 7, 2025 – The Board of Directors of Aquaporin A/S (“Aquaporin” or the “Company”), an innovative water technology company dedicated to rethinking water filtration with biotechnology, hereby provides an update on its strategic review.
As announced in company announcement no. 15/2025 dated August 11, 2025, the Company has initiated a strategic review and is currently exploring multiple opportunities in parallel to raise capital, including equity and/or through a strategic transaction or partnership. As part of this process, the Company is engaged in constructive dialogues with a group of existing shareholders and potential new investors. These discussions remain ongoing and no conclusions have been reached at this stage.
As a result of the current financial position of the Company, the Company has assessed that additional capital is needed from the beginning of 2026 to meet the Company’s ongoing capital needs and to support its future growth ambitions until profitability in the near- to mid-term. The Company is currently aiming for gross proceeds in the range of DKK 125 million to DKK 175 million and aims to complete a transaction, or a combination of transactions, before year end and in any case not later than the first half of 2026, subject to the necessary authorisations being granted, prevailing market conditions and investor sentiment.
As part of this process, the Company’s Board of Directors will today present a number of proposals for adoption at an extraordinary general meeting to be held on December 1, 2025. The proposals are motivated by the need to provide flexibility to accommodate a range of potential outcomes in structuring a transaction. A final decision on the transaction structure will depend on market conditions and the outcome of the ongoing discussions with various stakeholders as part of the strategic review, including the Company’s larger shareholders, potential new investors, and its financial adviser.
